Suboxone (Buprenorphine) Urine Detection Window: Factors and Variability

Buprenorphine (Suboxone®) is typically detectable in urine 1–4 days after last use, but the window can extend to 7–10 days in some individuals. Detection depends on multiple pharmacokinetic and behavioral variables.

Key Influencing Factors

• Dose and duration: Higher/longer use → accumulation in fat, prolonged excretion.
• Metabolism: CYP3A4 activity (genetic, drug interactions) affects clearance.
• Age, BMI, hydration: Higher adipose tissue and alkaline urine increase retention; dilute urine (high volume) lowers concentration but may prolong detectability.
• Urine pH: Acidic urine enhances renal elimination; alkaline urine reduces it.
• Co-administration: CYP3A4 inhibitors (azole antifungals, macrolides) raise levels; inducers (rifampin, carbamazepine) lower them.

Testing Nuances

• Standard immunoassays may not detect buprenorphine; specific buprenorphine/ norbuprenorphine assays (LC-MS/MS) are confirmatory.
• Cutoff concentrations vary by lab (often 5–10 ng/mL).
• Norbuprenorphine (major metabolite) is more abundant and extends detection.

For individualized interpretation, consult the ordering clinician or toxicology laboratory. Do not alter prescribed dosing based on anticipated testing.